NCT-Nummer	Name	Phase	Beschreibung / Name Phase	Therapie	Description (Setting, Phase)	Sites	Status (abgeschlossen/ rekrutierend)	Entität (HCC/ CCA)
NCT01167374	Carbon Ion Radiotherapy for HCC (PROMETHEUS-01)	I	PROMETHEUS	Heavy Ion Treatment (C12)	Locally advanced	HD	rekrutierend	HCC
NCT01556490	Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (STOP-HCC)	III	Stop HCC	TheraSpheres i.a.	Palliative therapy 1st -Line	H, TÜ, E	Rekrutierung beendet	HCC
NCT01658878	Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced HCC in Subjects with or without Chronic Viral Hepatitis	I	CA209-040-0030	Dose expansion Nivolumab, 1L Nivolumab vs Sorafenib	Anti-Programmed-Death-1 (PD-1) Antibody in Advanced HCC with or without Chronic Viral Hepatitis	E	follow up	HCC
NCT02112656	Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in HCC Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7	III	OPTIMA	RFA + ThermoDox vs. RFA + Dummy	Curative 1st line	TUM	rekrutierend	HCC
NCT02150967	Single Arm Study of BGJ398 in Patients With Advanced CC	II	CBGJ398X2204	BGJ393 (FGFR2 fusions or other FGFR alterations)	Palliative therapy 2nd -Line	HD	rekrutierend	CCA
NCT02170090	Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)	III	Acticca-1	Gem+Cis vs XELODA	Adjuvant therapy after resection CCC	H, HD,TÜ , MZ, L, HH, FFM, FR	rekrutierend	CCA
NCT02325739	FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression	I/II	CFGF401x2101	FGF401	Palliative therapy 2nd -Line (after Sorafenib)	H, HD, WÜ, E	zur Zeit pausiert	HCC
NCT02372162			E-med	Sorafenib or TACE	Palliative therapy 1st Line	TÜ	Rekrutierung beendet	HCC
NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	I	CIDH305X2101	IDH305 (IDH1+)	Palliative therapy 2nd -Line	HD	Rekrutierung pausiert	CCA, solid tumors
NCT02415036	Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable HCC or Intra Hepatic CC	II	PHP-HCC-202	Chemosaturation of liver	Unresectable HCC/ICC	H	Rekrutierung beendet	HCC, CCA
NCT02508467	BLU-554 in Patients With HCC	I	BLU-554-1101	Safety, tolerability, pharmacocinetics, pharmacodynamics and preliminary efficacy of Blu-554	Palliative therapy 2nd -Line	FFM	Rekrutierung pausiert	HCC
NCT02562755	Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)	III	PHOCUS	PexaVec vor Sorafenib	Palliative therapy 1st-Line	H, HD, TÜ, MZ, HH (rekrutierend), FFM, TUM	rekrutierend	HCC
NCT02746081	to determine the maximum tolerated or recommended Phase II dose of oral mutant IDH1 inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacokinetics and preliminary pharmacodynamic and anti-tumor activity in patients with IDH1-R132Xmutant advanced solid tumors; open-label, non-randomized, multicenter	I	BAY1436032 in IDH1-mutant advanced solid tumors	BAY1436032 in IDH1-R132Xmutant advanced solid tumors	Palliative therapy 2nd -Line	FFM, MHH, HD	rekrutierend	CCA, other solid tumors
NCT02924376	Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable CC Who Failed Previous Therapy	II	Incyte	INCB054828	Palliative unresectable CCC, 2nd, 3rd-Line	H, TÜ, MZ	rekrutierend	CCA
NCT02988440	A phase Ib study of PDR001 in combination with sorafenib in patients with advanced HCC	Ib	CPDR001G2101	Sorafenib + PDR001	safety and tolerability of PDR001 with sorafenib to identify the maximum tolerated dose and/or phase 2 dose for this combination in advanced Hepatocellular	E	rekrutierend	HCC
NCT03043547	Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC), AIO-HEP-0116 NAL-IRI	II	NALIRICC	Nal-IRI + 5-FU vs. 5-FU	Palliative 2nd line	TUM, H	rekrutierend	CCA

NCT-Nummer	Name	Phase	Beschreibung / Name Phase	Therapie	Description (Setting, Phase)	Sites	Status (abgeschlossen/ rekrutierend)	Entität (HCC/ CCA)
Registrierung in Vorbereitung	Intermittent treatment with sorafenib in combination with transarterial chemoembolization (TACE) in HCC: a randomized open-label	II	INTERSORTACE	TACE +/- Sorafenib	Palliative therapy 1st -Line	FFM	rekrutierend	HCC
Registrierung in Vorbereitung	5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): randomized, open-label	II	AIO-YMO/HEP-0316-IRIBIL	FOLFIRI versus 5-FU/Folinsäure	Palliative therapy 2nd -Line	FFM	rekrutierend	CCA
NCT02516813	An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors EMR100036-002	Ia/Ib	EMR100036-002	DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy	Palliative Therapy 2nd, 3nd, line	TÜ	rekrutierend	solid tumors
DRKS00008566	Response to sterotactic radiotherapy in HCC	n.a.	HERACLES	SBRT vs. TACE	prospective, non-interventional observational study	FR	Rekrutierung beendet	HCC
n.a.	Sample Collection for the Evaluation of Elecsys® PIVKA-II, AFP-L3 and AFP (HCC Biomarker Studie)	n.a.	CIM RD002542	n.a.	Sample collection	L, FR	rekrutierend	HCC
n.a.	TRANSFER II Study: Microsomal liver function in the 13C-methacetin breath test as a predictor of the survival of patients with advanced HCC under sorafenib therapy	n.a.	TRANSFER II	n.a.		WÜ , FR, MZ, ES, TUM; FFM	rekrutierend	HCC
n.a.	Vorhersagbarkeit des Ansprechens und der Verträglichkeit einer systemischen Therapie anhand des „Maximum Liver Function Capacity"(LiMAx)-Tests bei Patienten mit HCC	n.a.	LiMAx-Nr.1 (HCC)	systemische Therapie	prospective study	L	rekrutierend	HCC
n.a.	Vorhersagbarkeit des Ansprechens und der Verträglichkeit einer transarteriellen Chemoembolisation (TACE) anhand des „Maximum Liver Function Capacity"(LiMAx)-Tests bei Patienten mit HCC	n.a.	LiMAx-Nr.3 (TACE)	TACE	prospective study	L	rekrutierend	HCC
NCT03419897	Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously Treated Hepatocellular Unresectable Carcinoma	II	BGB-A312-208	1-2 Systemtherapien zuvor (mir	Einarmig Antikörper alle 3 Wochen	HH, MZ	Initiierung 06/18	HCC
NCT03412773	A Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable HCC	III	BGB-A312-301	Keine systemische Vortherapie	Zweiarmig Antikörper alle 3 Woche	HH	Initiierung 08/18	HCC
NCT03043547	A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies	II	NALIRICC	Gemcitabin oder Gemcitabin/Cis	Zweiarmig 1:1	HH	rekrutierend	CCA
NCT03473574	A randomized trial of durvalumab and tremelIMUMab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma	II	IMMUCHEC	Keine systemische Vortherapie	Dreiarmig 1:1:1	HH; TUM	rekrutierend	CCA
NCT01900158	A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex-induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy in Patients with Locally Advanced Inoperable Cholangiocarcinomas	I/II	PCI A202/12	PCI / Gemcitabine / Cisplatin	Locally advanced	Ffm; TUM	rekrutierend	CCA
NCT03298451	Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable HCC (HIMALAYA)	III	HIMALAYA	Durvalumab and Tremelimumab vs Sorafenib	Palliative therapy 1st -Line	MZ, L	rekrutierend	HCC
NCT03434379	A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or MetastaticHCC [IMbrave150]	III	IMbrave150	Atezolizumab in Combination With Bevacizumab vs Sorafenib	Palliative therapy 1st -Line	MZ, HH, L	rekrutierend	HCC
NCT03572582	A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage (HCC) (IMMUTACE)	II	IMMUTACE	TACE + Nivolumab	Palliative therapy 1st -Line	TUM; HH	rekrutierend	HCC